| 000 | 01856 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513165255.0 | ||
| 264 | 0 | _c19990506 | |
| 008 | 199905s 0 0 eng d | ||
| 022 | _a0031-6970 | ||
| 024 | 7 |
_a10.1007/s002280050561 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCazzola, M | |
| 245 | 0 | 0 |
_aOral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cJan 1999 |
||
| 300 |
_a829-33 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Inhalation |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlbuterol _xadministration & dosage |
| 650 | 0 | 4 |
_aArrhythmias, Cardiac _xchemically induced |
| 650 | 0 | 4 |
_aBronchodilator Agents _xadverse effects |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aForced Expiratory Flow Rates _xdrug effects |
| 650 | 0 | 4 |
_aForced Expiratory Volume _xdrug effects |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Diseases, Obstructive _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSalmeterol Xinafoate |
| 650 | 0 | 4 |
_aTerbutaline _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTremor _xchemically induced |
| 700 | 1 | _aCalderaro, F | |
| 700 | 1 | _aCalifano, C | |
| 700 | 1 | _aDi Pema, F | |
| 700 | 1 | _aVinciguerra, A | |
| 700 | 1 | _aDonner, C F | |
| 700 | 1 | _aMatera, M G | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 54 _gno. 11 _gp. 829-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002280050561 _zAvailable from publisher's website |
| 999 |
_c9988944 _d9988944 |
||